Novo Nordisk Broadens Arsenal with Implant Deal and MASH Approval as Buyback Sustains Momentum

Novo Nordisk counters Eli Lilly's market gains via a semaglutide implant deal, UK MASH approval for Wegovy, and restructuring in South Korea, supported by a $2B buyback.

Novo Nordisk is fighting back against Eli Lilly’s encroachment on multiple fronts — through a novel long-acting implant partnership, a new regulatory green light for Wegovy in Britain, and a restructuring in South Korea — all while a large share buyback program continues to cushion the stock. The Danish pharma giant’s latest moves signal a strategy that mixes near-term tactical defence with long-term pipeline diversification.

The most eye-catching initiative is a collaboration with California-based Vivani Medical to evaluate NPM-139, a Semaglutide implant designed for once- or twice-yearly administration. The device, built on Vivani’s NanoPortal platform, would target patients with chronic obesity who balk at daily or weekly injections. Vivani plans to start a Phase 1 clinical trial in humans by mid-2026, using injectable Wegovy as a comparator to gauge safety, tolerability and pharmacokinetics. The deal does not grant Novo Nordisk exclusivity over the technology or the drug candidate, and a market-ready product remains years away. Still, Vivani CEO Adam Mendelsohn characterised the agreement as a vote of confidence in his company’s approach. For Novo Nordisk, the implant represents an attempt to stretch its delivery technology beyond syringes and the oral Wegovy tablet — a hedge as Eli Lilly’s tirzepatide-based rivals continue to eat into its weight-loss market share.

On a more immediate front, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy for a new indication: adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe liver fibrosis. The approval is conditional on Novo Nordisk submitting further clinical data from ongoing studies, but it opens a potentially lucrative new market beyond weight loss. This regulatory win arrives as Novo Nordisk faces stiff competition in its core markets.

In South Korea, the company has merged its obesity and diabetes divisions and reshuffled management to speed decision-making and pool resources. The move is a direct response to Lilly’s rapid gains there: Mounjaro generated around 323 billion won in first-quarter sales, while Wegovy managed less than a third of that figure. A 40 percent price reduction for Wegovy failed to stem the loss of market share. Across the Atlantic, the picture is similarly challenging. In the United States, Lilly’s Zepbound now records over 100,000 more weekly prescriptions than Wegovy, giving its rival nearly 60 percent of the domestic market.

Alongside these commercial and regulatory battles, Novo Nordisk is leaning on a share buyback programme to support its stock. Between June 29 and July 3, 2026, the company repurchased one million B-shares, bringing its total treasury holding to roughly 40.2 million B-shares — about 0.9 percent of share capital. The programme, which runs until February 2027, has a total envelope of up to 15 billion Danish kroner and is widely seen as having propped up the share price in recent weeks.

Investors have taken notice. The stock closed at €42.77 on Wednesday, with a one-month gain of nearly 17 percent. On a weekly basis it edged down 2.86 percent, but the longer-term trend is more encouraging: the share price has surged more than 41 percent from its March low of €30.25, though it remains about 30 percent below the all-time high of €61.20 reached in July 2025. Year-to-date the stock is still down 4.27 percent, and compared with a year ago it is off 28.09 percent. Since the material dates of the two reports, the stock has pushed higher, trading around €43.13 with a one-month gain of 21 percent. Technical indicators show the recovery gaining momentum: the relative strength index has moved from 63.4 to 66, approaching overbought territory, and the share price sits comfortably above its 50-day and 200-day moving averages.

While the Vivani implant is a promising long-term bet, it will take years of clinical development before such a product reaches patients. In the meantime, Novo Nordisk’s combination of a new indication for Wegovy, internal restructuring and an active buyback should provide some near-term support. The coming half-year results will test whether the operational improvements can match the stock’s technical recovery.